Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

NCT07755202 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
AML With FLT3 Mutation

Interventions

COMBINATION_PRODUCT: gilteritinib-azacitidine-venetoclax

Sponsor

Florian Kuchenbauer